Ecnoglutide Reduces HbA1c and Body Weight in Type 2 Diabetes: Meta-Analysis

This systematic review and meta-analysis evaluated the efficacy and safety of ecnoglutide, a next-generation GLP-1 receptor agonist, in adults with type 2 diabetes (T2DM). The analysis included data from randomized controlled trials involving a total of 1643 participants. The comparator arms received either placebo or active comparators, though specific comparators were not detailed. The primary outcomes were changes in HbA1c and body weight.

For HbA1c, ecnoglutide produced a statistically significant reduction compared to control, with a mean difference (MD) of -0.44 (95% CI -0.55 to -0.33, p < 0.00001). Body weight also decreased significantly, with an MD of -5.63 kg (95% CI -7.90 to -3.35, p < 0.01). These results indicate clinically meaningful improvements in glycemic control and weight management.

Key secondary outcomes included fasting plasma glucose, which was significantly reduced (MD -0.81, 95% CI -1.03 to -0.59, p < 0.00001). Other secondary outcomes such as insulin resistance markers, lipid profile, and liver enzymes were assessed but specific numerical results were not reported in the available data.

Regarding safety, adverse events occurred more frequently with ecnoglutide compared to control (RR 1.09, p < 0.01). The adverse events were predominantly gastrointestinal and mild-to-moderate in severity. There were no significant differences in serious adverse events between groups. Discontinuation rates were not reported. The overall tolerability was described as acceptable.

Compared to prior landmark studies of GLP-1 receptor agonists, the magnitude of HbA1c reduction with ecnoglutide appears consistent with the class, while the weight reduction of approximately 5.6 kg is notable and may be favorable. However, direct head-to-head comparisons with other GLP-1 agonists are lacking in this analysis.

Methodological limitations include the absence of detailed information on study settings, follow-up duration, and specific comparators. The meta-analysis may be subject to heterogeneity across trials, and the lack of individual patient data limits subgroup analyses. Additionally, the long-term efficacy and safety beyond the trial periods remain unknown.

Clinically, these findings support the therapeutic potential of ecnoglutide as a next-generation GLP-1 receptor agonist for T2DM, particularly for patients who require both glycemic control and weight reduction. The gastrointestinal side effect profile is consistent with the class and manageable in most patients.

Unanswered questions include the durability of weight loss, cardiovascular outcomes, and comparative effectiveness against other GLP-1 agonists. Further studies with longer follow-up and broader populations are needed to establish ecnoglutide's place in therapy.